Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

Reply to Scalone and Cortesi : Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy : The importance of using updated and adequate social tariffs to calculate QALYs

F. Spandonaro
F. Ayala
E. Berardesca
S. Chimenti
G. Girolomoni
P. Martini
A. Peserico
B. Polistena
A.P. Guerra
G.A. Vena
G. Altomare
P.C. Pinton

February 2015

Comment on: Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: ...

Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View

Lemaître, F.
Tron, C.
Rayar, M.

January 2017

International audienceTo the Editor: We read with interest the article by Tremblay et al [1] recent...

Correspondence Class of Antiretroviral

Cd+ T Cell

September 2016

To the Editor—I would like to con-gratulate Khanna et al. [1] for their study, which investigated ri...

Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

Cojutti, Pier Giorgio
Rinaldi, Matteo
Zamparini, Eleonora
Rossi, Nicolò
Tedeschi, Sara
Conti, Matteo
Pea, Federico
Viale, Pierluigi

January 2022

We thank Baklouti et al. (1) for commenting on our population pharmacokinetic study of dalbavancin f...

Estimation of the Loading Dose for Target-Controlled Infusion of Dexmedetomidine. Reply to Eleveld et al. Comment on “Morse et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. J. Clin. Med. 2020, 9, 3480”

James D. Morse
L. Ignacio Cortinez
Brian J. Anderson

July 2021

The parameters for a three-compartment model described by Morse and colleagues [...

Reply to Dr Hatipoglu et al and to Dr Mancini et al

Brienza, Nicola
Dalfino, Lidia
Puntillo, Filomena
Bruno, Francesco

January 2016

First, we would like to remark that our study aim was uniquely to investigate the renal toxicity of ...

Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections

Cojutti, Pier Giorgio
Rinaldi, Matteo
Zamparini, Eleonora
Rossi, Nicolò
Tedeschi, Sara
Conti, Matteo
Pea, Federico
Viale, Pierluigi

January 2021

Background: Dalbavancin is gaining interest in the treatment of complex osteoarticular (OA) infectio...

Jacques Schrenzel
Daniel Lew

January 2015

We thank Parra-Ruiz et al.1 for their useful comments on alter-native antimicrobial therapy for orth...

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model

Stillemans, Gabriel
Belkhir, Leïla
Vandercam, Bernard
Vincent, Anne
Haufroid, Vincent
Elens, Laure

January 2021

PURPOSE: A variety of diagnostic methods are available to validate the performance of population pha...

Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?"

Märtson, A G
Boonstra, J M
Sandaradura, I
Kosterink, J G
van der Werf, T S
Marriott, D J E
Zijlstra, J G
Touw, D J
Alffenaar, J W C

May 2021

We thank Van Daele et al (1) for their interest in our study investigating the pharmacokinetics in c...

Reply to Simon, Shah et al,

To The Editor—because An Important

September 2016

role of models is to elucidate and explore factors, processes, and relationships in a decision and g...

Reply to Dr. Megarbane et al. regarding "Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose"

Isbister, Geoffrey K.
Friberg, Lena E.
Duffull, Stephen B.

January 2007

Megarbane et al. suggest in their letter that pharmacokinetic–pharmacodynamic (PKPD) analysis in ind...

Reply:

Adler, Frederick R.
Remien, C. H.

January 2012

pre-printWe appreciate the comments of Drs. Craig and Simpson and Drs. Mullins and Schwartz, and the...

Reply to “Successful Target Attainment of Telavancin at Elevated MICs: Fact or Fiction?”

September 2016

In reading Dr. Farkas ’ letter, he cites two concerns with the ex-posure target (AUC/MIC of 219) emp...

Reply toMoonan andWeis, Seaworth et al, and

Phillips

September 2016

and Weis for their comments [1] on our recent publication [2]. First, regardless of its excellent pe...

Reply to Scalone and Cortesi : Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy : The importance of using updated and adequate social tariffs to calculate QALYs

F. Spandonaro
F. Ayala
E. Berardesca
S. Chimenti
G. Girolomoni
P. Martini
A. Peserico
B. Polistena
A.P. Guerra
G.A. Vena
G. Altomare
P.C. Pinton

February 2015

Comment on: Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: ...

Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View

Lemaître, F.
Tron, C.
Rayar, M.

January 2017

International audienceTo the Editor: We read with interest the article by Tremblay et al [1] recent...

Correspondence Class of Antiretroviral

Cd+ T Cell

September 2016

To the Editor—I would like to con-gratulate Khanna et al. [1] for their study, which investigated ri...

Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

Cojutti, Pier Giorgio
Rinaldi, Matteo
Zamparini, Eleonora
Rossi, Nicolò
Tedeschi, Sara
Conti, Matteo
Pea, Federico
Viale, Pierluigi

January 2022

We thank Baklouti et al. (1) for commenting on our population pharmacokinetic study of dalbavancin f...

Estimation of the Loading Dose for Target-Controlled Infusion of Dexmedetomidine. Reply to Eleveld et al. Comment on “Morse et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. J. Clin. Med. 2020, 9, 3480”

James D. Morse
L. Ignacio Cortinez
Brian J. Anderson

July 2021

The parameters for a three-compartment model described by Morse and colleagues [...

Reply to Dr Hatipoglu et al and to Dr Mancini et al

Brienza, Nicola
Dalfino, Lidia
Puntillo, Filomena
Bruno, Francesco

January 2016

First, we would like to remark that our study aim was uniquely to investigate the renal toxicity of ...

Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections

Cojutti, Pier Giorgio
Rinaldi, Matteo
Zamparini, Eleonora
Rossi, Nicolò
Tedeschi, Sara
Conti, Matteo
Pea, Federico
Viale, Pierluigi

January 2021

Background: Dalbavancin is gaining interest in the treatment of complex osteoarticular (OA) infectio...

Jacques Schrenzel
Daniel Lew

January 2015

We thank Parra-Ruiz et al.1 for their useful comments on alter-native antimicrobial therapy for orth...

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model

Stillemans, Gabriel
Belkhir, Leïla
Vandercam, Bernard
Vincent, Anne
Haufroid, Vincent
Elens, Laure

January 2021

PURPOSE: A variety of diagnostic methods are available to validate the performance of population pha...

Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?"

Märtson, A G
Boonstra, J M
Sandaradura, I
Kosterink, J G
van der Werf, T S
Marriott, D J E
Zijlstra, J G
Touw, D J
Alffenaar, J W C

May 2021

We thank Van Daele et al (1) for their interest in our study investigating the pharmacokinetics in c...

Reply to Simon, Shah et al,

To The Editor—because An Important

September 2016

role of models is to elucidate and explore factors, processes, and relationships in a decision and g...

Reply to Dr. Megarbane et al. regarding "Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose"

Isbister, Geoffrey K.
Friberg, Lena E.
Duffull, Stephen B.

January 2007

Megarbane et al. suggest in their letter that pharmacokinetic–pharmacodynamic (PKPD) analysis in ind...

Reply:

Adler, Frederick R.
Remien, C. H.

January 2012

pre-printWe appreciate the comments of Drs. Craig and Simpson and Drs. Mullins and Schwartz, and the...

Reply to “Successful Target Attainment of Telavancin at Elevated MICs: Fact or Fiction?”

September 2016

In reading Dr. Farkas ’ letter, he cites two concerns with the ex-posure target (AUC/MIC of 219) emp...

Reply toMoonan andWeis, Seaworth et al, and

Phillips

September 2016

and Weis for their comments [1] on our recent publication [2]. First, regardless of its excellent pe...

Reply to Scalone and Cortesi : Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy : The importance of using updated and adequate social tariffs to calculate QALYs

F. Spandonaro
F. Ayala
E. Berardesca
S. Chimenti
G. Girolomoni
P. Martini
A. Peserico
B. Polistena
A.P. Guerra
G.A. Vena
G. Altomare
P.C. Pinton

February 2015

Comment on: Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: ...

Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View

Lemaître, F.
Tron, C.
Rayar, M.

January 2017

International audienceTo the Editor: We read with interest the article by Tremblay et al [1] recent...

Correspondence Class of Antiretroviral

Cd+ T Cell

September 2016

To the Editor—I would like to con-gratulate Khanna et al. [1] for their study, which investigated ri...

Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

Abstract

Extracted data

Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

Abstract

Extracted data

Related items

Related items